RxDoctor Payments Data

Akindolapo Akinwande, MD

Cardiovascular Disease · Indianapolis, INNPI 1891766309

Payments from drug & device makers

$1,396in general payments, 2019–2025

Across 69 payments — averaging $20.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$606
  • Novartis$190
  • Regeneron Healthcare Solutions, Inc.$125
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$106
  • Abbott$98
  • Boehringer Ingelheim$54
  • plus $218 from 8 others

What the payments were for

  • Food & beverage$1,396100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,396 in reported general payments places this provider in the 35th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$85,705
Medicare patients
368
Services billed
894

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban377$379,393
JardianceEmpagliflozin235$187,578
EntrestoSacubitril/Valsartan91$65,765
XareltoRivaroxaban40$49,450
FarxigaDapagliflozin Propanediol39$25,319
BrilintaTicagrelor27$21,149
VascepaIcosapent Ethyl30$14,358
Metoprolol Succinate655$6,011
Diltiazem 24hr Er (Cd)Diltiazem Hcl73$2,753
Clonidine19$2,568
Cardura XlDoxazosin Mesylate11$2,240
Furosemide473$2,019
Atorvastatin Calcium301$1,844
Spironolactone340$1,844
Carvedilol321$1,472

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$379,393377 claims
Boehringer IngelheimJardiance$54$187,578235 claims
NovartisEntresto$190$65,76591 claims
Johnson & JohnsonXarelto$43$49,45040 claims
AstraZenecaFarxiga, Brilinta$40$46,46866 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →